Course InformationTherapautic Area: Cardiology
Format(s): Meeting Reporter
Credit(s): 1.0 AMA PRA Category 1 Credit(s)™
Activity Dates: May 10, 2017-May 9, 2018
This Official Elsevier Clinical Perspectives and Analysis will cover data presented at the American College of Cardiology 66th Annual Scientific Sessions and Expo held in Washington, DC. The four expert faculty will discuss the most up to date statistics and therapeutic advances for patients with preserved ejection fraction heart failure. The faculty will debate measures of prognosis and biomarkers to enhance treatment plans. Current clinical trial data will be examined in cross reference with new and emerging combination therapies to better serve patients. Upon completion of this activity physicians will gain a better understanding of treatment options to provide better outcomes for patients with ejection fraction heart failure.
Cardiologists, primary care physicians, and other healthcare professionals who care for patients with heart failure.
Upon completion of this activity, participants will be able to:
- Discuss biomarkers, prognostic indicators and classification criteria for the treatment of reduced or preserved ejection fraction heart failure.
- Analyze clinical trial data of current and emerging combination therapies for the treatment of heart failure, including its role in reducing risk of hospitalizations, presented at ACC 2017.
- Develop optimal therapeutic strategies to manage patient-specific disease to improve outcomes for patients with preserved ejection fraction heart failure.
James Louis Januzzi, MD
Director, Dennis and Marilyn Barry Fellowship in Cardiology Research
Massachusetts General Hospital
Ileana L. Piña, MD, MPH
Professor, Department of Medicine
Montefiore Medical Center
Scott David Solomon, MD
Professor, Harvard Medical School
Director, Noninvasive Cardiology
Brigham and Women’s Hospital